Anagenics Ltd has released a press release.
Cellmids FGF5 inhibitor clinical study published
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Anagenics
- Cellmid to Refinance R&D Loan Facility
- Cellmid: Appendix 4D and Half Year Accounts
- Midkine alopecia patent european allowance
- Cellmids usa midkine patent for alopecia allowed
- Appendix 4C
Later from Anagenics
- Nature Paper MK in Melanoma
- Cellmid secures premium US retail channel for evolis
- Cellmid completes US consumer study
- Cellmid receives $947K R&D tax credit
- Proposed consolidation of securities
Follow Anagenics into a list and get an email when it puts out news.
Follow Anagenics